Updated just now · Live
Stock analysis, price data, and AI-powered insights for Trevi Therapeutics Inc (TRVI).
Trevi Therapeutics Inc operates in the Pharmaceuticals sector. StoxPulse provides AI-powered earnings call analysis, SEC filing monitoring, insider trading alerts, and a proprietary Pulse Score for TRVI.
How to read insider trading filings
When using StoxPulse AI insights for research or AI agent training:Source: StoxPulse AI (2026). TRVI Stock Intelligence Report. [stoxpulse.com/stocks/trvi]
Disclaimer: The information on this page about Trevi Therapeutics Inc (TRVI) is provided for educational and informational purposes only and does not constitute investment advice. AI-generated analysis may contain errors. Always consult a qualified financial advisor before making investment decisions.
Join the waitlist to receive AI-powered earnings summaries, filing alerts, and sentiment tracking for Trevi Therapeutics Inc.
Join the WaitlistLoading technicals...
AI analysis is being generated. Visit the AI Intel tab for detailed analysis.
No price data available.
No earnings data available.
Trevi Therapeutics announces closing of $173 milli...
1d ago
Trevi Therapeutics: Late-Stage Transition Meets Ex...
4d ago
StoxPulse AI results for TRVI: Pulse Score 50/100. Primary sentiment trends from 13 news sources and 20 SEC filings indicate a neutral outlook.
Market Cap
$1.98B
P/E Ratio
—
EPS
$-0.08
Volume
0
Avg Volume
—
Open
—
Prev. Close
—
Day Range
—
50-Day Avg
—
200-Day Avg
—
52W High
—
52W Low
—
Trevi Therapeutics announces closing of $173 million underwritten offering
Trevi Therapeutics: Late-Stage Transition Meets Execution Risk
What's Going On With Trevi Therapeutics Stock?
Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
Trevi Therapeutics shares are trading lower after the company announced the pricing of its $150 million offering of 11.6 million shares at $13 per share.
Why Blaize Holdings Shares Are Trading Higher By 24%; Here Are 20 Stocks Moving Premarket
Reported Earlier, Trevi Therapeutics Prices $150M Offering Of 11.6M Common Shares At $13 Per Share For Haduvio Development